MedWatch

Ambu fails to live up to revenue forecasts

The number of endoscopes sold is significantly higher than what the market had predicted in Ambu's second quarter. However, this has not brought about the kind of revenue that analysts had expected. The full-year outlook is maintained.

Photo: PR / Ambu

Ambu maintains its full-year outlook following a Q2 in which revenue totaled DKK 1bn.

However, the firm underperformed revenue-wise compared the DKK 1.016bn that analysts had expected. Ambu only provided DKK 1.001bn (USD 163.3m) in the second quarter of the company's staggered fiscal year. However, this is still progress compared to the DKK 989m from the same time period last year.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs